By Bry'onna Mention ·Updated December 16, 2021
Sanofi and Regeneron Pharmaceuticals recently published the results of the clinical trial for Dupixent, or Dupilumab, a treatment for children between ages 6 and 11 with moderate to severe uncontrolled asthma.
Findings revealed significantly reduced asthma attacks.
Of the 408 children in the study, an average 65% of severe asthma attacks decreased over one year versus a placebo, STAT reported. After a six month period, more children
